What does Ousia Pharma do?
Ousia Pharma is a Copenhagen-based biotechnology company focused on developing a new class of peptide-drug conjugates aimed at treating obesity and metabolic diseases by leveraging incretin hormone analogues to deliver neuroplasticity modulators directly to the brain's appetite control centers.
How much did they raise?
The company raised an undisclosed amount in a Seed funding round led by Omega Funds, with notable board additions including former top executives from AstraZeneca, which underscores the strategic support behind the round.
What are their plans for the money?
With the new funding, Ousia Pharma intends to advance the preclinical and clinical development of its once-weekly dual-incretin-NMDA receptor antagonist conjugate, potentially offering a novel therapeutic option for obesity and metabolic disorders.
What have they achieved so far?
Ousia Pharma has transitioned from its academic origins as a spin-out from the University of Copenhagen and has already established a promising drug-targeting approach, positioning it as a forward-thinking player in the biotech sector.
